AP/News-Observer Examines State Of Vaccine Research

email to a friend

printer friendly

opinions

Current Article Ratings:

Patient / Public:		5 (1 votes)
Healthcare Prof:		5 (1 votes)

The Associated Press/News-Observer examines revitalized vaccine research, including for such conditions as malaria, TB and HIV. "Vaccines are no longer a sleepy, low-profit niche in a booming drug industry. Today, they're starting to give ailing pharmaceutical makers a shot in the arm," according to the article. The AP/News-Observer looks at specific company focal points and vaccine sales forecasts as well as how "[t]he lure of big profits, advances in technology and growing government support has been drawing in new companies, from nascent biotechs to Johnson & Johnson" to vaccines.

Emilio Emini, Pfizer's head of vaccine research, said, "Even if a small portion of everything that's going on now is successful in the next 10 years, you put that together with the last 10 years [and] it's going to be characterized as a golden era."

According to AP/News-Observer, "many companies are partnering with promising biotechs, the World Health Organization and global charities, or setting up deals with local drugmakers abroad, to inexpensively manufacture vaccines in developing and middle-tier countries that increasingly want them to prevent much-higher health care costs" (Johnson, 11/20).

This information was reprinted from globalhealth.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives and sign up for email delivery at globalhealth.kff.org.

© Henry J. Kaiser Family Foundation. All rights reserved.

• Additional
• References
• Citations